به جمع مشترکان مگیران بپیوندید!

تنها با پرداخت 70 هزارتومان حق اشتراک سالانه به متن مقالات دسترسی داشته باشید و 100 مقاله را بدون هزینه دیگری دریافت کنید.

برای پرداخت حق اشتراک اگر عضو هستید وارد شوید در غیر این صورت حساب کاربری جدید ایجاد کنید

عضویت

فهرست مطالب bahareh bigdeli

  • Nakisa Rezakhani *, Bahram Goliaei, Fereshte Mahdizade, Alireza Nikoofar, Hoda Keshmiri Neghab, -MohammadHasan Soheilifar, Seyedeh Sara Azadeh, Bahareh Bigdeli
    Introduction

    Breast cancer is one of the most prevalent diseases around the world. Breast cancer patients treated with radiation may face Side effects as well as cancer recurrence. Some polyphenols exhibit antioxidant effects. Citrus and Orthosiphon Stamineus have source of methylated flavone called Sinensetin (SIN). In this research, we designation of Sinensetin as increasing radiation sensitivity.

    Material and Methods

    The cytotoxic effect of Sinensetin was examined in MDA-MB-231 and T47D by MTT assay. As well as, the clonogenic ability of cells were Assessmented in the presence of Sinensetin and combination with radiation. To quantify expression alterations of apoptosis related genes, utilized Real-Time PCR method.

    Results

    In a dose and time-dependent manner, Sinensetin decreased the viability of MDA-MB-231 and T47D. The survival fraction was decreased in cells treated with Sinensetin (SIN) prior to X-irradiation compared to cells treated with X-ray only. More ever, expression level of, Bcl-2, STAT3, and increased P53 via treated cells with Sinensetin (SIN) and X-ray.

    Conclusion

    Due to the results, Sinensetin (SIN) can be mentioned as a novel radiosensitizer and its effects may considered increasing apoptosis following DNA damage induced by irradiation.

    Keywords: Breast Cancer X, Radiation Sinensetin Radio Sensitizer Agent Flavonoids}
  • Fereshte Mahdizade Valojerdi *, Bahram Goliaei, Nakisa Rezakhani, Alireza Nikoofar, Hoda Keshmiri Neghab, Mohammad Hasan Soheilifar, Bahareh Bigdeli
    Background
    Radiotherapy is a frequently used therapeutic modality for breast cancer. Dalbergin, a natural antioxidant, inhibits carcinogens and tumor progression. In the present study, we investigated the effect of Dalbergin on the response of T47D and MDA-MB-231 breast cancer cell lines to ionizing radiation.
    Method
    In this experimental in vitro study, doubling time of T47D and MDAMB- 231 were obtained from the growth curve. The cytotoxic effect of Dalbergin on T47D and MDA-MB-231 breast cancer cells were estimated via MTT assay. To determine the clonogenic ability, we treated T47D and MDA-MB-231 with Dalbergin for 48 h prior to irradiation, subsequent to which a colony assay was performed. Real-time polymerase chain reaction was employed to determine the gene expression level.
    Results
    Dalbergin inhibited proliferation of T47D and MDA-MB-231 in a time and concentration-dependent manner. Additionally, the most appropriate time for the treatment of these types of cancer cells was found to be 48 h and the drug's concentration in both cell lines was different. The IC50 values of T47D and MDA-MB-231 cells were 0.001 and 0.0001 μM, respectively. Moreover, this drug radiaosensitizes both cell lines effectively compared with the radiation only. Finally, the gene expression level of p53, Bcl-2, and STAT3 were investigated in cancer cells.
    Conclusion
    Dalbergin showed apoptotic effects probably through the STAT/p53 signaling pathway. Therefore, Dalbergin could be considered as a radiosensitizer and its effects may be owing to increased cell death.
    Keywords: Dalbergin, Cells, X-rays, Apoptotic, Cell death}
بدانید!
  • در این صفحه نام مورد نظر در اسامی نویسندگان مقالات جستجو می‌شود. ممکن است نتایج شامل مطالب نویسندگان هم نام و حتی در رشته‌های مختلف باشد.
  • همه مقالات ترجمه فارسی یا انگلیسی ندارند پس ممکن است مقالاتی باشند که نام نویسنده مورد نظر شما به صورت معادل فارسی یا انگلیسی آن درج شده باشد. در صفحه جستجوی پیشرفته می‌توانید همزمان نام فارسی و انگلیسی نویسنده را درج نمایید.
  • در صورتی که می‌خواهید جستجو را با شرایط متفاوت تکرار کنید به صفحه جستجوی پیشرفته مطالب نشریات مراجعه کنید.
درخواست پشتیبانی - گزارش اشکال